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Phytochemicals are dietary phytoestrogens that may play a role in prostate cancer prevention.
Forty percent of Americans use complementary and alternative medicines (CAM) for disease
prevention and therapy. Ashwagandha (Withania somnifera) contains flavonoids and active
ingredients like alkaloids and steroidal lactones which are called ‘Withanolides’. We hypothesize
that the immunomodulatory and anti-inflammatory properties of Ashwagandha might
contribute to its overall effectiveness as an anti-carcinogenic agent. The goal of our study
was gain insight into the general biological and molecular functions and immunomodulatory
processes that are altered as a result of Ashwagandha treatment in prostate cancer cells, and to
identify the key signaling mechanisms that are involved in the regulation of these physiological
effects using genomic microarray analysis in conjunction with quantitative real-time PCR and
western blot analysis. Ashwagandha treatment significantly downregulated the gene and protein
expression of proinflammatory cytokines IL-6, IL-1b, chemokine IL-8, Hsp70 and STAT-2,
while a reciprocal upregulation was observed in gene and protein expression of p38 MAPK,
PI3K, caspase 6, Cyclin D and c-myc. Furthermore, Ashwagandha treatment significantly
modulated the JAK-STAT pathway which regulates both the apoptosis process as well as the
MAP kinase signaling. These studies outline several functionally important classes of genes,
which are associated with immune response, signal transduction, cell signaling, transcriptional
regulation, apoptosis and cell cycle regulation and provide insight into the molecular signaling
mechanisms that are modulated by Ashwagandha, thereby highlighting the use of this
bioflavanoid as effective chemopreventive agent relevant to prostate cancer progression.
Keywords: Ashwagandha–bioflavonoids–genomics–immunomodulation–microarrays–
prostate cancer–signal transduction
Introduction
The latest statistics from the American Cancer Society
estimates that a total of 218 890 new cases of prostate
cancer and 27050 deaths from the disease are anticip-
ated in the United States in 2007, making it the most
frequent nondermatologic cancer among US males (1,2).
Prostate cancer is about twice as common among
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properly cited.African-American men as it is among white American
men and exhibits tremendous differences in incidence
among populations worldwide (1–3). This profound
geographic and racial variation in prostate cancer risk
has stimulated investigations into how diet affects the
development and progression of prostate cancer (4,5).
Phytochemicals are dietary phytoestrogens that may
play a role in prostate cancer prevention (6–10). Plant
compounds inhibit carcinogenesis via several mechanisms
including antioxidant activity, changes in carcinogen
metabolism, modulation of the cell cycle, alterations
in intracellular signaling, and inhibition of angiogenesis
(10–15). Approximately 40% of Americans use comple-
mentary and alternative medicines (CAM) for disease
prevention and therapy. Over 5000 flavonoids, the largest
class of phenolics, have been described (16–19).
Polyphenols that are effective when given during the
post-initiation period, inhibiting tumor promotion and
progression, appear to be more useful in preventing
cancer in humans than polyphenols that are effective only
when given before and during carcinogen exposure (20).
Ashwagandha (Withania somnifera)—known as Indian
ginseng is cultivated in India and North America, and
whose roots have been used for thousands of years by
Ayurvedic practitioners (21,22). Ashwagandha’s root con-
tains flavonoids and many active ingredients like alkaloids
and steroidal lactones which are commonly called
Withanolides (16). The chemicals constituents of Ashwa-
gandha include three natural powerful antioxidants-
superoxide dismutase, catalase and glutathione peroxidase
(17–19). Ashwagandha may have chemopreventive proper-
ties that make it a potentially useful adjunct for patients
undergoing radiation and chemotherapy (15, 20).
Our previous studies have evaluated the antiprolifera-
tive properties of various flavonoids (23,24), and have
indicated that flavonoids can modulate cell cycle regula-
tion making them potential anti-cancer agents.
To obtain a comprehensive view of the possible
molecular and biological processes that are modulated
by Ashwagandha treatment to prostate cells, we per-
formed genomic analysis using a cDNA microarray. The
use of the microarray technology allowed us to rapidly
screen large numbers of potentially relevant genes that
are involved in the controlling of certain key biological
processes, this gives us an insight into the general
physiological and immunomodulatory processes that are
altered as a result of Ashwagandha treatment of prostate
cancer cells. In the present study, we have attempted to
outline specific groups of genes whose expression is
significantly regulated by Ashwagandha in a highly
invasive prostate cancer cell line PC-3. These studies
show that several functionally important classes of genes,
which are associated with immune response, signal
transduction, cell signaling and transcriptional regulation,
apoptosis and cell cycle regulation, can be important
targets in bioflavonoid therapy.
Material and Methods
Cell Culture
The human prostate cancer cell line, PC-3 is obtained
from the American Type Culture Collection (Manassas,
VA). Approximately 3 10
6 cells per 60mm dish are
cultured at 37 C in a humidified atmosphere of 5% CO2
and 95% air for 48h. Only cell suspensions >90% viable
are used for experiments.
Dietary Bioflavonoid
The alcoholic extract of Ashwagandha was a gift from
Sami Labs Limited (Bangalore, India). In brief, dried root
powder was extracted with ethyl alcohol at 60–70 C three
times and all the three extracts combined. The combined
extract was concentrated by distillation of the solvent in
Rota vapor under reduced pressure. This extract was stored
at –20 C and was stable for several months. For each assay,
the extract was freshly solubilized in DMSO and utilized at
a 0.5–1mg/ml concentration.
RNA Extraction
Cytoplasmic RNA is extracted by an acid guanidinium-
thiocyanate-phenol-chloroform method as described (25)
using Trizol reagent and stored at –80 C until used.
cDNA Microarrays
The gene microarrays (Roswell Park Cancer Institute;
Microarray and Genomics Core Facility) consisted of
 5043 cDNA clones (Invitrogen, Carlsbad, CA) which
were selected based on their association with cancer
progression. A total of six RNA samples that included
the three sets of Ashwagandha-treated (1mg/ml) PC-3
cells and three sets of untreated controls. cDNA was
synthesized from each of those RNA samples and the
Ashwagandha-treated samples were labeled with Cy5,
while the corresponding untreated controls were labeled
with the Cy3 dye. To minimize intra-array variations,
two hybridizations for each sample were performed, and
additionally the labeling with the Cy dyes was inter-
changed, so as to have technical replicates of the matched
pairs of Ashwagandha-treated and untreated samples.
Microarray Data Processing and Analysis
Expression data extracted from image files were first
checked by an M (log2(Cy3/Cy5)) versus A((log2 (Cy3)+
log2 (Cy5))/2) plot to see whether intensity-dependent
expression bias existed between spots (genes) labeled with
Cy3 and Cy5 on each individual slide. Data normal-
ization was done to correct the intensity-dependent
expression bias. After data normalization, the average
178 Anti-proliferative effects of Ashwagandhaintensity of individual gene from multiple spots on each
slide was computed using an in-house developed PERL
script. A total of 5043 average expression values were
obtained. Paired t-test on normalized intensity with low
P-values was used to generate a list of genes with
significant change in expression between normal and
Ashwagandha-treated samples. The false positive rate
(FDR) of the significant genes was estimated by using the
SAM algorithm. Detailed normalization approaches have
been described in our previous publication (26–28).
Real-time, Quantitative RT-PCR
Gene expression was quantitated using real-time PCR.
Relative expression of mRNA species was calculated
using the comparative CT method (29). All data were
controlled for quantity of RNA input by performing
measurements on an endogenous reference gene, b-actin.
Western Blot Analysis
PC-3 cells were cultured with Ashwagandha (1mg/ml) for
48h, cells lysed and 30mg of total extracted protein was
separated on 4–20% gradient polyacrylamide gel (30) and
electroblotted to PVDF membranes which were further
probed with specific primary antibodies against the
proteins of interest.
Cell Proliferation Assays
PC-3 cells are plated at a density of  1000 cells/well in
96-well plates and incubated with varying concentrations
of Ashwagandha (0.5–1mg/ml) in complete medium for
24h. Cell viability is quantified using the MTS assay
[Promega CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay (Cat.# G5421); Promega, Madison,
WI] as described previously (31,32).
Results
Ashwagandha Inhibits Cell Proliferation
PC3 cells (1000 cells/well) were plated in a 96-well plate and
treated with Ashwagandha extract at concentrations
ranging from 0.5 to 1mg/ml for 24h. The results of our
cell proliferation assay show that Ashwagandha treatment
significantly inhibited cell proliferation in a dose-depen-
dent manner (Fig. 1). The percentage inhibition at 0.5 and
1mg/ml Ashwagandha concentrations was 39% and 68%,
respectively. Supplementation of medium with 0.2%
DMSO, which was used as the solvent had no detectable
effect on cell proliferation or on the cell morphology.
Modulation of Gene Expression in PC-3 Cells
Treated with Ashwagandha
To compare gene expression levels between Ashwagandha-
treated PC-3 cells and their respective untreated controls.
Treatment of PC-3 cells with 0.2% DMSO had no
detectable effect on PC-3 cells and consequently this
group was not used in subsequent studies. We used the
regularized paired t-test (28) to detect differentially
expressed genes, which resulted in 266 significant genes
with low P-values. For multiple test correction to control
the FDR, these genes were further subjected to SAM
analysis, which resultedin ashorterlist of249 geneswith an
estimated <1% FDR. Out of these 249 differentially
expressed genes, 137 (55.02%) were up-regulated and 112
(44.57%) were down-regulated with Ashwagandha treat-
ment, as shown in Fig. 2 in black and gray color,
respectively. These results indicate that based on statistical
analysis a large number of genes were differentially exp-
ressed between Ashwagandha-treated and untreated cells.
The differentially expressed genes have been subdivided
into various functional categories. Table 1 outlines the fold
change in the gene expression of significantly modulated
genesthatareinvolvedin cellcycle regulation,regulation of
apoptosis, modulation of stress proteins, cytokine and
chemokine regulation, regulation of signal transduction,
regulation of structural proteins, and oncogene regulation.
Categorization of Differentially Expressed Genes Based
on the Biological and Molecular Function
To enhance biological interpretation of the differentially
expressed genes from our cDNA microsarray studies, we
sought to see if any of the biological processes or
molecular function were over-represented by the
Figure 1. Ashwagandha treatment inhibits cell proliferation in PC-3
cells. Results show that treatment with Ashwagandha significantly
decreased cell proliferation. Data are the mean   SD of three separate
experiments done in triplicate. Statistical significance was determined by
ANOVA.
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a function enrichment analyses for these genes using
a functional classification tool. DAVID 2.0 (33).
Our results indicated that, although there were many
over-represented biological function categories as can
been seen from Table 2, majority of them are related to
a few major function categories. The most relevant
function categories include immune response, protein
kinase cascade, regulation of apoptosis, and regulation of
cell cycle.
Analysis of Microarray Data Using Functional
Annotational Clustering
We further analyzed our microarray data using func-
tional annotation clustering for our differentially
expressed genes to see if any of these genes could be
clustered together, thus establishing biological links
between genes. The resulting gene clusters are shown in
Table 3, in which the group enrichment scores which
rank the genes based on their biological significance are
also listed. The results of this analysis outline, two groups
of genes that are tightly coupled. The first group of genes
included caspase recruitment domain family, member 4;
receptor-interacting serine-threonine kinase 2; casp8 and
fadd-like apoptosis regulator; mitogen-activated protein
kinase kinase 5; cell division cycle 2-like 5, while the
second group of genes displaying tight coupling included
signal transducer and activator of transcription 2 and
c-myc binding protein.
Mapping Signaling Pathways Using
Functional Genomics Data
Biological implications can also be deduced from
biochemical pathways triggered by the list of genes
modulated by Ashwagandha treatment. By looking at
the over-representation of genes in pathways, we could
obtain direct or indirect insight into the physiological
functions of these significantly modulated genes. Using
yet another feature of the DAVID functional annotation
tool called DAVID Pathway Viewer, a short list of
significant pathways (Table 4) was obtained which
displays key functional genes from the entire list of
significantly modulated genes (249 in this case) on
pathway maps thus facilitating biological interpretation
in a network context. Our results show that our genes
were significantly enriched along three distinct pathways.
They are JAK-STAT pathway, the apoptosis pathway
and the MAPK signaling pathway. Among these the
JAK-STAT pathway appears to be the key because it not
only modulates both the apoptosis process and the
MAPK signaling but also is the signaling pathway that
is most significantly modulated as indicated by the
P-value<0.0037 (Table 4 and Fig. 3).
Ashwagandha Modulates Gene and Protein Expression of
a Group of Cytokines, Chemokines, Apoptotic Markers,
Cell Cycle Proteins and Signal Transduction Molecules
Based on the functional annotation analysis using
DAVID as described above, a group of genes that
modulate the JAK-STAT signaling pathway and regulate
key biological and molecular functions were selected.
They included IL-6, IL-8, IL-1b, STAT 2, p38 MAPK,
PI3K, Caspase 6, Hsp70, Cyclin D, and c-myc. These
genes are significantly modulated by Ashwagandha
treatment as shown by gene array analysis. To further
validate our findings, we performed quantitative real-time
PCR using specific PCR primers and western blot
analysis for protein expression for these key regulatory
genes. Our results presented in Fig. 4 show that PC-3
cells treated with 1mg/ml Ashwagandha displayed down-
regulation of gene expression of the proinflammatory
cytokines IL-6 (55% down-regulation, P<0.002), IL-1b
(41% down-regulation, P<0.05), chemokine IL-8
(32% down-regulation, P<0.04) and stress heat shock
protein Hsp70 (23% down-regulation, P<0.02).
Ashwagandha treatment also down-regulated Signal
Transducer and Activator of Transcription 2 (STAT-2)
(34% down-regulation, P<0.01), a dual function protein
that regulates signal transduction and activates transcrip-
tion as part of a phosphorylation cascade. The genes
that were significantly upregulated with Ashwagandha
treatment were p38 MAPK (69% upregulation,
P<0.013); PI3K (51% upregulation, P<0.04) caspase
6 (44% upregulation, P<0.03); Cyclin D (71% upregu-
lation, P<0.006) and c-myc (29% upregulation,
P<0.043). The respective percent increases in protein
expression for each these genes are shown in Fig. 5. Our
results show that PC-3 cells treated with 1mg/ml
Ashwagandha downregulated the protein expression of
Figure 2. Distribution of differentially expressed genes shown as a
scatter plot representation of the average log2 ratio between normal and
Ashwagandha-treated PC-3 cells for the 249 genes. Statistically
significant genes (P-value<0.01) identified by two-step analyses of
t-test and SAM are shown in color, including down-regulated genes
(in grey) and up-regulated genes (in black). Dashed lines indicate
two-fold changes.
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Gene Acession no Gene nomenclature Physiological function Fold change in gene expression
Cell cycle regulation
AI340905 Cyclin D3 D-type cyclins are essential for progression from G1
to S-phase. They bind to and activate both CDK4
and CDK6.
1.32 "
AA489042 Cell division cycle 2-like 5 Cell division controller 1.09 "
AA704459 Chromatin assembly factor
1, subunit A (p150)
One of the replication-coupled assembly factors
involved in the reconstitution of S-phase chromatin
0.85 #
AA450265 Proliferating cell nuclear
antigen
PCNA gene is induced by p53 and plays a key role
in the control of eukaryotic DNA replication
0.86 #
Regulation of apoptosis
AA626710 Caspase 6 Apoptosis-related cysteine protease 1.21 "
AA453766 CASP8 and FADD-like
apoptosis regulator
A caspase-like molecule known to bind to
Fas-associated protein with death domain
0.87 #
Modulation of stress proteins
AA456298 H2B histone family,
member Q
Basic nuclear proteins that are responsible for the
nucleosome structure of the chromosomal fiber in
eukaryotes
1.41 "
AI276745 Prostaglandin E receptor 2 PGE(2) regulates cellular immune responses
through Distinct EP receptors
1.25 "
AA398410 Heat shock transcription
factor 2 binding protein
Heat-shock transcription factors (HSFs) bind to
heat-shock elements (HSE) that are promoter sites
for heat-shock proteins; important in differentiation
and development
1.24 "
H50114 Glutamate receptor, ionotro-
pic, N-methyl D-aspartate
2C
Regulates NMDA receptor and cell trafficking and
ion channel properties
1.23 "
AA620511 Heat shock 70kD protein 8 Molecular chaperone. 0.91 #
R33642 Glutathione S-transferase pi GSTs bind flavonoid natural products in the
cytosol prior to their deposition in the vacuole; are
components of ultraviolet-inducible cell signalling
pathways and are potential regulators of apoptosis;
cell survival by GST-P is due to alleviation of
oxidative stress and/or JNK activition
0.87 #
Cytokines and chemokine regulation
AA128153 Interleukin 1 receptor-like 1 Receptor for interleukin-33 (IL-33), its stimulation
recruits MYD88, IRAK1, IRAK4, and TRAF6,
followed by phosphorylation of MAPK3/ERK1
and/or MAPK1/ERK2, MAPK14, and MAPK8
1.30 "
AA015914 Fibroblast growth factor 1
(acidic)
Potent mitogen and is involved in the regulation of
key cellular process such as angiogenesis, differ-
entiation, and morphogenesis
1.25 "
AA630120 Vascular endothelial growth
factor B
Up-regulation of urokinase Plasminogen Activator
and its inhibitor plasminogen activator inhibitor-1
(PAI-1), which suggests a role in endothelial cell
migration and matrix remodeling
1.18 "
AA102526 Interleukin 8 Pro-inflammatory cytokine involved in the cellular
response to inflammation, being a powerful
chemoattractant for neutrophils
0.86 #
AI668847 Small inducible cytokine
subfamily B (Cys-X-Cys)
RNA binding, RNA-dependent DNA replication,
cell-cell signaling, chemokine activity, chemotaxis,
extracellular, immune response, inflammatory
response, signal transduction, transferase activity
0.59 #
T72877 Interleukin 1 receptor
antagonist
Neutralizes biological activity of IL1 a & b in
physiologic and pathophysiologic immune and
inflammatory responses
0.80 #
AI074784 Colony stimulating factor 3
(granulocyte)
Cytokines and Inflammatory Response, Regulation
of hematopoiesis by cytokines
0.75 #
(continued)
eCAM 2010;7(2) 181the proinflammatorycytokinesIL-6(72%downregulation,
P<0.01), IL-1b (39% downregulation, P<0.05), chemo-
kine IL-8 (52% downregulation, P<0.03), Hsp70 (63%
downregulation, P<0.01) and STAT-2
(38% downregulation, P<0.05). The proteins that
were significantly upregulated with Ashwagandha treat-
ment were p38 MAPK (49% upregulation, P<0.03);
PI3K (56% upregulation, P<0.02) caspase 6
Table 1. Continued
Gene Acession no Gene nomenclature Physiological function Fold change in gene expression
AA150507 Interleukin 1, beta Pro-inflammatory cytokine that mediates acute
phase response
0.75 #
Signal transduction modulation
H80263 Phosphatidylinositol-4-phos-
phate 5-kinase, type II, beta
Cell surface receptor linked signal transduction 1.34 "
AA913804 Receptor-interacting serine-
threonine kinase 2
Regulation of apoptosis and protein amino acid
phosphorylation
1.34 "
H18633 Protein tyrosine phosphatase,
receptor type, B
Regulation of tyrosine kinase signals 1.28 "
AA134814 TRAF family member-asso-
ciated NFKB activator
NF-kappaB activation through IKK-i-dependent
I-TRAF/TANK phosphorylation
1.26 "
AI381043 Inositol 1,4,5-trisphosphate
3-kinase A
Serves both as a second messenger and as a
substrate for inositol polyphosphate kinases
1.24 "
AA489245 Mitogen-activated protein
kinase 8 interacting protein 3
Activation of JNK via IL-1b; JNK-mediated
proapoptotic stimuli.
1.22 "
AA709036 Regulator of G-protein
Signalling 10
Regulator of G protein Signaling, RGS4 type 1.21 "
AA434420 Protein tyrosine phosphatase,
non-receptor type 9
Regulates responses to extracellular signals by
regulating the phosphotyrosine content of specific
intracellular proteins
1.14 "
AA927490 Signal transducer and acti-
vator of transcription 2,
113kD
JAK-STAT signaling pathway 0.89 #
AA182847 Mitogen-activated protein
kinase kinase kinase kinase 5
MAPKS are extracellular signal-regulated kinases
(ERKs) that act as an integration point for multiple
biochemical signals because they are activated by a
wide variety of extracellular signals, are rapidly
phosphorylated on threonine and tyrosine residues
0.84 #
AA039851 Protein tyrosine phosphatase
type IVA, member 3
Prenylated protein tyrosine phosphatases (PTPs);
regulatory role in a variety of cellular processes;
modulates angiotensin-II induced cell calcium
mobilization and cell growth
0.83 #
AA022666 IKK-related kinase epsilon;
inducible IkappaB kinase
Transcription factor that plays an important role in
the immune, anti-apoptotic and inflammatory
responses.
0.74 #
AA419268 Phosphoinositide-3-kinase, Control the activity and subcellular localisation of
a diverse array of signal transduction molecules;
implicated in a wide range of cellular processes,
including cell cycle progression, cell growth, cell
motility, cell adhesion and cell survival
0.73 #
AA487426 Rho GDP dissociation
inhibitor
Caspase Cascade in Apoptosis, FAS and TNFR1
Signaling Pathway
0.68 #
Oncogene regulation
AA020001 C-myc binding protein C-myc is a cellular proto-oncogene strongly impli-
cated in the control of cellular proliferation,
programmed cell death, and differentiation
1.23 "
W46900 GRO1 oncogene Regulates growth factor activity 0.56 #
Regulation of structural proteins
AA598978 Filamin A, alpha Actin-binding protein-280 0.89 #
W31391 Zona occludens 2 Regulation of tight junctions 0.86 #
AA001432 Laminin, alpha 3 Basement membrane protein 0.74 #
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tion, P<0.01) and c-myc (23% upregulation, P=0.06).
We observed concordance between gene expression and
protein expression levels in the Ashwagandha-treated PC-3
cells. Furthermore, these results showed similar trends in
gene expression as those obtained by our microarray
analysis thus validating our gene microarray results
presented in Table 1.
Statistical Analysis
All statistical analysis for the above data was performed
using analysis of variance (ANOVA), following the
Mann–Whitney U-test to determine the statistical differ-
ence between control and treated groups. P<0.05 was
considered significant.
Discussion
Withania somnifera Dunal, which is commonly known as
Ashwagandha is reported to have antitumor, anti-stress,
immunomodulatory, anti-inflammatory and antibacterial
effects (11–15). The roots of W. somnifera contain several
alkaloids, withanolides, a few flavanoids and reducing
sugars (14–19). Several studies support the role of
ashwagandha as an effective cancer chemopreventive
agent, however limited information is available regarding
the mechanism of regulation of these chemopreventive
effects (20). The goal of our study was gain insight into
the general biological and molecular functions and
immunomodulatory processes that are altered as a
result of Ashwagandha treatment in prostate cancer
cells, and to identify the key signaling mechanisms that
are involved in the regulation of these physiological
Table 4. DAVID Pathway Viewer lists key signaling pathways that are
modulated by ashwangandha treatment
Signaling pathways Genes (%) P-value
JAK-STAT Signaling pathway 11.6 3.7E 3
Apoptosis 7.2 1.3E 2
MAPK Signaling pathway 10.1 1.8E 2
Table 2. Functional annotation classification based on physiological
function of significantly regulated genes.
Classifications gene
count (%)
P-value
Biological Processes
Response to stress 29.0 1.4E 5
Immune response 26.1 5.7 E 5
Regulation of biological process 47.8 3.0E 5
Protein kinase cascade 11.6 2.3E 4
Intracellular signaling cascade 21.7 3.0E 4
Inflammatory response 10.1 3.3E 4
Regulation of signal transduction 10.1 4.5E 4
Cell surface receptor linked
signal transduction
26.1 5.2E 4
Regulation of I-kappaB
kinase/NF-kappaB cascade
7.2 5.3E 4
Regulation of cell proliferation 10.1 2.0E 3
Regulation of cellular physiological process 37.7 3.0E 3
Regulation of cell cycle 11.6 4.3E 3
Regulation of apoptosis 10.1 4.5E 3
Regulation of cell adhesion 4.3 1.2E 2
Molecular functions
Signal transducer activity 47.8 3.0E 8
Protein binding 52.2 4.1E 6
Cytokine activity 11.6 3.8E 5
Receptor binding 17.4 5.0E 5
Growth factor activity 10.1 7.9E 5
Protein kinase activity 17.4 1.4E 3
Protein tyrosine phosphatase activity 5.8 6.7E 3
Inositol or phosphatidylinositol
kinase activity
4.3 9.5E 3
Chemokine receptor binding 4.3 1.4E 2
Chemokine activity 4.3 1.4E 2
G-protein-coupled receptor binding 4.3 2.0E 2
Protein serine/threonine kinase activity 8.7 2.7E 2
Table 3. Functional annotation clustering
Gene Accesssion no P-value
Enrichment Score: 1.95
AA699441 Caspase recruitment domain family,
member 4
1.5E 3
AA913804 Receptor-interacting serine-threonine
kinase 2
1.9E 3
AA453766 casp8 and fadd-like apoptosis
regulator
2.6E 3
AA182847 Mitogen-activated protein kinase
kinase kinase kinase 5
1.3E 3
AA489042 Cell division cycle 2-like 5 1.5E 2
Enrichment Score: 1.55
AA927490 Signal transducer and activator of
transcription 2
1.3E 3
AA020001 c-myc binding protein 4.5E 2
Using the DAVID 2.0 annotation system, functional annotational
clustering of the significantly regulated genes. The group enrichment
score represents the geometric mean (in log scale) of member’s P-values
in a corresponding annotation cluster. This is used to rank their
biological significance. The Functional Annotation Clustering integrates
the techniques of Kappa statistics to measure the degree of the common
genes between two annotations, and fuzzy heuristic clustering to classify
the groups of similar annotations according to kappa values. Thus, the
more common genes annotations share, the higher chance they will be
grouped together. The P-values associated with each annotation terms
inside each clusters are obtained using the Fisher’s Exact test or/EASE
Score. In DAVID annotation system, the Fisher’s Exact test is adopted
to measure the gene-enrichment in annotation terms.
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contain numerous molecules that are antiproliferative the
biological effect that we observed could be due to one or
many compounds. The effect could also be additive in
nature. However, on initial reverse phase HPLC analysis
of the alcohol extract we observed that the anti-
proliferative effect was confined to a compound that
eluted at 10.7min, giving a peak at m/z of 567 (data not
given). Therefore, it is our conviction that the majority of
the antiproliferative and the effects on gene expression
that we observed in this study is due to this particular
compound; further characterization of the compound is
ongoing in our laboratory.
Our results showed that Ashwagandha treatment
modulated several functionally important classes of
genes, which are associated with cell cycle regulation,
regulation of apoptosis, modulation of stress proteins,
cytokine and chemokine regulation, regulation of signal
transduction, and oncogene regulation in prostate cancer
cells (PC-3). Additionally, a good concordance was
observed between our microarray data, and the results
obtained using both our validation methodologies,
namely the real time PCR analysis and the Western
blot analysis, however some of the protein expression
levels did not show the extent of changes as seen in the
gene expression level. This could possibly be due to the
post-transcriptional or post-translational modification
associated with protein expression. Analysis of our
microarray data using functional annotation clustering
showed significantly modulated gene clusters and pro-
vides group enrichment scores which rank the genes
based on their biological significance. These analyses
further confirm the important role played by genes that
regulate apoptosis, cell signaling and signal transduction
in the Ashwagandha-mediated immunomodulation.
Using the function annotation tool DAVID Pathway
Viewer, we were able to highlight key signaling pathways
via which the immunomodulatory effects of
Ashwagandha are mediated. Our results show three
distinct pathways that are significantly modulated; they
are JAK-STAT pathway, the apoptosis pathway and the
MAPK signaling pathway. Among these the JAK-STAT
pathway appears to be key because it also modulates
both the apoptosis process and the MAPK signaling.
Figure 3. Schematic representation of the genes regulated by Ashwagandha extract in JAK-STAT signaling pathway. The genes highlighted with an
asterisk (*) are significantly regulated by Ashwagandha and are important in the regulation of cell proliferation, regulation of apoptosis and
immunomodulation.
Figure 4. Ashwagandha treatment significantly modulates gene expres-
sion in PC-3 cells. Graphical representation of quantitative changes in
gene expression by real-time PCR. Relative mRNA species expression
was quantitated and expressed as transcript accumulation index (TAI=
2
–CT), calculated using the comparative CT method. All data were
controlled for quantity of RNA input by performing measurements on
an endogenous reference gene, b-actin. In addition, results on RNA
from Ashwagandha-treated samples were normalized to results obtained
on RNA from the control, untreated sample. Data are the mean SD
of three separate experiments done in triplicate. Statistical significance
was determined by ANOVA.
184 Anti-proliferative effects of AshwagandhaAshwagandha treatment significantly downregulated the
gene and protein expression of proinflammatory cytokines
IL-6, IL-1b, chemokine IL-8, Hsp70 and STAT-2, while
a reciprocal upregulation was observed in gene and protein
expression of p38 MAPK, PI3K, caspase 6, Cyclin D and
c-myc. Several in vitro studies show that polyphenols can
modulate oncogenes, tumor suppressor genes, cell cycling,
apoptosis, angiogenesis and associated signal transduction
pathways (34,35). Tyagi et al. (36) showed that the
anticancer effects of grape seed extract (GSE) on moder-
ately aggressive DU-145 prostate cancer cells were due to
activation of the JNK pathway, resulting in growth
inhibition and apoptosis. Recent studies demonstrated
that flavonoids can inhibit proliferation of other cancers by
interfering with tubulin binding and subsequent micro-
tubule assembly (37), among the 249 genes that were
significantly modulated by Ashwagandha, several were
structural proteins, like filamin A, laminin and tight
junction protein-zona occludens 2. The significant anti-
tumor effects of flavonoids are attributed to the modula-
tion of protein tyrosine phosphorylation (38). Suppression
of carcinogenesis by tumor suppressor genes is mediated by
constraining tumor cell proliferation and colony forma-
tion. The tumor suppressor genes, suppresses tumor
growth by modulating the phosphatidylinositol 3-kinase
(PI3K) and causes G1 cell cycle arrest and cell death
(39–41). The cyclin D gene encodes a regulatory subunit of
the CDK4 and CDK6 holoenzyme complex that phos-
phorylates and inactivates the tumor suppressor protein,
pRB, thereby modulating cell cycle progression into late
G1 and S phases (41–43).
Ashwangandha treatment down regulates the expres-
sion of the proinflammatory cytokines IL-6, IL-8 and
IL-1b hereby acting as a immunomodulator, via the
dynamic regulation of these cytokines. These cytokines
are crucial to innate and adaptive inflammatory
responses, cell growth and differentiation, cell death,
angiogenesis and developmental as well as repair
processes. The janus kinase/signal transducer and acti-
vator of transduction (JAK/STAT) pathway is a intra-
cellular signal-transducing pathway that is activated by
oxygen radicals, various cytokines, and growth factors in
various disease states (44,45). Originally described as the
regulator for cytokine signaling, JAK/STAT pathway is
now recognized as an important membrane-to-nucleus
signaling pathway for a variety of stress responses and
oxidative stress. STAT proteins have the dual function of
signal transduction and activation of transcription as part
of a phosphorylation cascade (44). Ashwagandha down-
regulates the expression of STAT2 which is a potent
transactivator and forms stable homodimers which
complex with adaptor protein p48 and bind to the
interferon-stimulated response element (ISRE) thereby
modulating cell proliferation and immunity.
Figure 5. Ashwagandha treatment significantly modulates protein expression in PC-3 cells. Graphical representation of quantitative changes in
protein expression by Western blot analysis. Data are the mean SD of three separate experiments done in triplicate. Statistical significance was
determined by ANOVA.
eCAM 2010;7(2) 185Stress-inducible heat-shock protein 70 (Hsp70) has
gained plenty of attention as a putative target for
tumor therapy since it is an important regulator of
cancer cell growth. Expression of Hsp70 in tumor cells
has been proposed to enhance their immunogenicity and
prevent tumor cell death (46). Ashwagandha treatment
significantly decreases the gene and protein expression of
Hsp70, which may result in the generation of a specific
immune response by promoting apoptosis. The oncogene
c-myc gene participates in most aspects of cellular
function, including replication, growth, metabolism,
differentiation, and apoptosis (34,35). Our studies high-
light that treatment of PC-3 cells with Ashwagandha
results in the activation of c-Jun N-terminal kinase (JNK)
signaling, indicating that it may be the key signaling
pathway involved in the process leading to activation of
apoptosis in these cancer cells. Thus, plant-derived
antioxidants can modulate biochemical and physiological
processes that may affect cancer progression. Based on its
pro-apoptotic and its immunomodulatory effects,
Ashwagandha can be considered to be useful as novel
complementary therapy for integrative oncology care.
Furthermore, based on this preliminary finding we would
like to characterize the active ingredient using reverse
phase HPLC separation. The eluted compound which
shows the presence of active ingredients would be further
characterized using the NMR and the mass spectroscopy
to elucidate the structure of the molecule.
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